Thousand Oaks, CA, United States · Est. 1980 · 27,000 employees
One of the world's leading biotechnology companies.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 5 drugs with upcoming expirations
Pipeline
By Phase
24 drugs in development
By Therapeutic Area
top 6
R&D Momentum
87/100
Pipeline Velocity
64/100
Trial Completion Rate
85/100
Pipeline Concentration
16/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis
An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
A Phase 1, Randomized, Double-blind, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Maridebart Cafraglutide After Switching From Glucagon-like Peptide-1 Receptor Agonists in Participants Living With Overweight or Obesity
8-K
A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity
An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Xaluritamig in Adult, Adolescent and Pediatric Participants With Relapsed or Refractory Ewing Sarcoma
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 691 Administered in Healthy Chinese and Japanese Participants
Details
Company Overview
$165.0B
Mkt Cap
$23.7B
Revenue
$12.0B
Cash
Therapeutic Focus
Recent SEC Filings
8-K
8-K
8-K
8-K
AMGEN INC (AMGN) (CIK 0000318154)
Pipeline
Regulatory
Blincyto — BLINCYTO
Application BLA125557
Aimovig — AIMOVIG
Application BLA761077
Aimovig — AIMOVIG
Application BLA761077
Aimovig — AIMOVIG
Application BLA761077
Aimovig — AIMOVIG
Application BLA761077
Blincyto — BLINCYTO
Application BLA125557
Blincyto — BLINCYTO
Application BLA125557
Blincyto — BLINCYTO
Application BLA125557
Blincyto — BLINCYTO
Application BLA125557
Aimovig — AIMOVIG
Application BLA761077
Blincyto — BLINCYTO
Application BLA125557
Tavneos — TAVNEOS
Application NDA214487
Aranesp — ARANESP
Application BLA103951
Blincyto — BLINCYTO
Application BLA125557
Blincyto — BLINCYTO
Application BLA125557
Otezla — OTEZLA XR
Application NDA210745 (NDA)
Aimovig — AIMOVIG
Application BLA761077
Blincyto — BLINCYTO
Application BLA125557
Aimovig — AIMOVIG
Application BLA761077
Vectibix — VECTIBIX
Application BLA125147
8-K
Accession: 0000318154-26-000153
8-K
Accession: 0000318154-26-000144
8-K
Accession: 0000318154-26-000124
8-K
Accession: 0000318154-26-000119
AMGEN INC (AMGN) (CIK 0000318154)
Accession: 001-37702
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)